Cancer vaccine cuts melanoma risk nearly 50% in breakthrough study

Name: Cancer vaccine cuts melanoma risk nearly 50% in breakthrough study
Uploaded: 2026-06-02T17:34:17Z
Duration: 49 s
Description: A new injectable therapy is showing positive results in reducing melanoma throughout a five-year period. The personalized mRNA cancer therapy, combined with the cancer immunotherapy drug KEYTRUDA, is a collaboration between Merck and Moderna.

FNC · Jun 2, 2026 · 49s

Sign Up Now

Already a subscriber?

A new injectable therapy is showing positive results in reducing melanoma throughout a five-year period. The personalized mRNA cancer therapy, combined with the cancer immunotherapy drug KEYTRUDA, is a collaboration between Merck and Moderna.